Pulmonary Pharmacology and Therapeutics Pulmonary Pharmacology and Therapeutics RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Real-world evaluation of the clinical safety and efficacy of fluticasone/formoterol FDC via the Revolizer® in patients with persistent asthma in India
Publication date: Available online 30 November 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Aloke Ghoshal, Pradyut Waghray, George Dsouza, Mahip Saluja, Mayank Agarwal, Ashish Goyal, Sneha Limaye, Akash Balki, Sudhir Bhatnagar, Manish Jain, Sharad Tikkiwal, Abhijit Vaidya, Meena Lopez, Rashmi Hegde, Jaideep GogtayAbstractThe combination of inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABAs) is widely used for the management of asthma. This prospective, open-label, non-comparative, observational, 24-week multicentre study is the first real-world study from India to compare the efficacy and sa...
Source: Pulmonary Pharmacology and Therapeutics - December 1, 2019 Category: Respiratory Medicine Source Type: research

C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD
ConclusionWe did not find a reduced risk of moderate and/or severe COPD exacerbations among COPD patients with varying CRP levels currently exposed to ICS. However, low-grade systemic inflammation was associated with all-cause mortality among COPD patients. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 29, 2019 Category: Respiratory Medicine Source Type: research

Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series
ConclusionsEndobronchial administration of ε-aminocaproic acid during bronchoscopy may be a safe and efficacious option in the treatment and prevention of pulmonary bleeding. Further studies are necessary to better define ε-aminocaproic acid's safety profile, optimal routes of administration, and comparative effectiveness to tranexamic acid. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 26, 2019 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: December 2019Source: Pulmonary Pharmacology & Therapeutics, Volume 59Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 16, 2019 Category: Respiratory Medicine Source Type: research

Antistatic treatment and salbutamol dosing have variable effect on drug delivery of valved holding chambers
ConclusionVHCs marketed as antistatic are significantly affected by antistatic treatment. To ensure optimal drug delivery, salbutamol should be actuated to VHCs one puff at a time. Each VHC brand has its unique characteristic that affects drug delivery in a way that cannot be generalised to another VHC. There is a need for universal standardisation of VHCs.Key notesValved holding chambers (VHCs) that are marketed as antistatic are significantly affected by antistatic treatment. Multiple actuations before inhalation tend to decrease the drug delivery efficacy of VHCs. Each VHC brand has its unique characteristic that affect...
Source: Pulmonary Pharmacology and Therapeutics - November 1, 2019 Category: Respiratory Medicine Source Type: research

Interfering with airway nerves in cough associated with asthma
Publication date: Available online 1 November 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Akio Niimi, Kensuke Fukumitsu, Norihisa Takeda, Yoshihiro KanemitsuAbstractCough is a troublesome and often refractory symptom of asthma, which is associated with poor control of disease. The pathogenesis of asthmatic cough has mainly been attributed to bronchoconstriction, but recent evidence indicate that cough reflex hypersensitivity or neuronal dysfunction is a feature of asthma, even in those with mild stable disease. This is likely resistant to the mainstay treatment ICS/LABA which inhibits classic asthmatic resp...
Source: Pulmonary Pharmacology and Therapeutics - November 1, 2019 Category: Respiratory Medicine Source Type: research

Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis
ConclusionsThe results of this meta-analysis show that LABA/LAMA combinations are consistently more effective than ICS/LABA FDCs for most of the evaluated outcomes. However, differences have also been observed between FDCs belonging to the same class. Across the investigated LABA/LAMA FDCs, glycopyrronium/indacaterol revealed a consistent and robust efficacy profile. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 20, 2019 Category: Respiratory Medicine Source Type: research

Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques
Publication date: Available online 15 October 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Martina Oriano, Leonardo Terranova, Giovanni Sotgiu, Laura Saderi, Angela Bellofiore, Mariangela Retucci, Cinzia Marotta, Andrea Gramegna, Daniela Miglietta, Chiara Carnini, Paola Marchisio, James D. Chalmers, Stefano Aliberti, Francesco BlasiAbstractNeutrophil elastase (NE) is a crucial marker of neutrophilic inflammation. We aimed to compare different techniques to detect active NE in sputum samples of 50 Bronchiectasis (BE) and 50 Cystic Fibrosis (CF) patients. Three methods including a ProteaseTag® Active NE Immun...
Source: Pulmonary Pharmacology and Therapeutics - October 16, 2019 Category: Respiratory Medicine Source Type: research

Emerging targets for cough therapies; NK1 receptor antagonists
Publication date: Available online 14 October 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Huda Badri, Jaclyn A. SmithAbstractCough is mediated by vagal afferent fibres innervating the larynx and proximal airways. Pre-clinical studies suggest that vagal C fibres produce Substance P, one of the tachykinin family of neuropeptides, which has been shown to enhance cough via the neurokinin-1 (NK-1) receptor and studies in animal models have also shown that NK-1 antagonists are effective at blocking induced cough. In the past, tachykinin receptor antagonists have yielded disappointing results in treating asthma an...
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2019 Category: Respiratory Medicine Source Type: research

Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands
ConclusionXC8 was safe and well tolerated. A phase 2 study is being performed to further evaluate the potential role of XC8 in asthma treatment.Trial registrationClinicalTrials.gov, NCT02882217. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 7, 2019 Category: Respiratory Medicine Source Type: research

Progress in cough hypersensitivity at the Tenth London International Cough Symposium 2018 (10th LICS 2018)
Publication date: Available online 26 September 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Kian Fan Chung, Lorcan McGarvey, Stuart B. Mazzone (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 27, 2019 Category: Respiratory Medicine Source Type: research

Comparison of anti-inflammatory mechanisms between doxofylline and theophylline in human monocytes
ConclusionsIn conclusion, our data support the growing hypothesis that doxofylline does not have a superimposable mechanism of action compared to theophylline, and this may both explain some differences in the risk/benefit ratio and may direct studies to tailor therapy for patients. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 27, 2019 Category: Respiratory Medicine Source Type: research

Isolated airways in equine respiratory pharmacology: They never lie
Publication date: Available online 22 September 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Luigino Calzetta, Elena Pistocchini, Beatrice Ludovica Ritondo, Paola Roncada, Giuseppe Cito, Domenico Britti, Maria Gabriella MateraAbstractPre-clinical studies on human isolated bronchi have relevant translational value in human in vivo, conversely no investigation has been performed to assess whether data resulting from equine isolated airways can have any translational application in asthmatic horses. Thus, a meta-regression analysis via random-effect method was carried out to correlate the pharmacological charac...
Source: Pulmonary Pharmacology and Therapeutics - September 24, 2019 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: October 2019Source: Pulmonary Pharmacology & Therapeutics, Volume 58Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 22, 2019 Category: Respiratory Medicine Source Type: research

Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice
ConclusionTaken together, these results suggested that inhibition of the PD-1/PD-L1 signaling pathway enhanced the innate immune response of alveolar macrophages to Mycobacterium TB in mice. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 18, 2019 Category: Respiratory Medicine Source Type: research